Legend Biotech Corp
NASDAQ:LEGN

Watchlist Manager
Legend Biotech Corp Logo
Legend Biotech Corp
NASDAQ:LEGN
Watchlist
Price: 23.36 USD -2.18% Market Closed
Market Cap: 4.3B USD

Legend Biotech Corp
Accounts Receivables

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Legend Biotech Corp
Accounts Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Legend Biotech Corp
NASDAQ:LEGN
Accounts Receivables
$6.3m
CAGR 3-Years
-50%
CAGR 5-Years
-27%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Accounts Receivables
$12.8B
CAGR 3-Years
6%
CAGR 5-Years
9%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Accounts Receivables
$5.1B
CAGR 3-Years
5%
CAGR 5-Years
5%
CAGR 10-Years
-2%
Amgen Inc
NASDAQ:AMGN
Accounts Receivables
$8.5B
CAGR 3-Years
17%
CAGR 5-Years
16%
CAGR 10-Years
11%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Accounts Receivables
$1.9B
CAGR 3-Years
12%
CAGR 5-Years
20%
CAGR 10-Years
28%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Accounts Receivables
$5.7B
CAGR 3-Years
1%
CAGR 5-Years
7%
CAGR 10-Years
15%
No Stocks Found

Legend Biotech Corp
Glance View

Legend Biotech Corp., an emerging leader in the biotechnology arena, has carved out a niche at the forefront of cellular therapeutics, focusing on transforming cancer treatment paradigms. Born out of the ambition to explore innovative medical frontiers, Legend Biotech embarked on a mission to develop Car-T cell therapies—a personalized form of immunotherapy that employs genetically altered T-cells to target and eradicate cancer cells. With its signature product, Carvykti (ciltacabtagene autoleucel), Legend Biotech has been making waves in the oncology sector. By redirecting the body's own immune system against multiple myeloma, a rare and challenging form of cancer, the company has demonstrated the potential to achieve deep and lasting remissions, bringing hope where conventional treatments may fall short. The financial model of Legend Biotech is driven by strategic partnerships, extensive research and development initiatives, and successful navigation through complex regulatory landscapes. Partnering with Johnson & Johnson's subsidiary Janssen Biotech, the collaboration capitalizes on their combined expertise to advance Car-T technology. Revenues primarily flow from milestone payments upon achieving specific developmental goals, along with royalties derived from global sales of their breakthrough treatments. By investing heavily in R&D and ensuring a robust pipeline of therapeutic candidates, Legend Biotech positions itself for sustainable growth, striving to extend their innovative treatments to a broader range of cancers and, eventually, achieve profitability through expanded indications and market reach.

LEGN Intrinsic Value
HIDDEN
Show

See Also

What is Legend Biotech Corp's Accounts Receivables?
Accounts Receivables
6.3m USD

Based on the financial report for Dec 31, 2024, Legend Biotech Corp's Accounts Receivables amounts to 6.3m USD.

What is Legend Biotech Corp's Accounts Receivables growth rate?
Accounts Receivables CAGR 5Y
-27%

Over the last year, the Accounts Receivables growth was -94%. The average annual Accounts Receivables growth rates for Legend Biotech Corp have been -50% over the past three years , -27% over the past five years .

Back to Top